Centogene
Centogene Plans Further Cost-Cutting Measures, Seeks Additional Funding Amidst Rising H1 Revenues
For the first half of 2023, Centogene reported a 15 percent year-over-year increase in revenues, driven by both its pharma and diagnostics business segments.
In Brief This Week: Quest Diagnostics; Centogene; Exact Sciences; Eiger Diagnostics
News items for the week of Aug. 28, 2023.
Centogene Regains Compliance With Nasdaq Listing Requirements
The company had already regained compliance with Nasdaq's requirements once before this year, after missing the minimum bid price requirement last December.
Centogene Receives Noncompliance Notice From Nasdaq Over Market Value of Shares
The market value of the company's publicly held shares has fallen below $15 million for 30 consecutive business days, triggering the notification.
In Brief This Week: Biocept, Quest, Agilent, MDxHealth, OpGen, More
News items for the week of May 15, 2023.
Apr 28, 2023
Centogene Receives Nasdaq Noncompliance Notice
Dec 19, 2022
Centogene Gets Nasdaq Non-Compliance Notice
Dec 16, 2020